Back to Research Hub
Kodiak Sciences Inc.
KOD
$31.06+1.45 (+4.90%)
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related…
StreetsValue research for Kodiak Sciences Inc. (KOD)
Members get the full report for Kodiak Sciences Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.